A US-based KOL gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Pipeline therapies discussed include BTK inhibitor + BCL-2 inhibitor + CD20 mAb triplet regimens, noncovalent BTK inhibitors, and CD19-directed CAR-T therapy. 

This interview was conducted on 24 May 2024. 

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.